-
Mashup Score: 0
FDA-approval of Novartis’ Pluvicto, FDA approval of PYLARIFY, piflufolastat F18 in prostate cancer clinical trials with lutetium Lu 177 vipivotide tetraxetan, PYLARIFY for the selection of patients with prostate cancer.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Lantheus Announces PYLARIFY AI™ is Now Available - 2 year(s) ago
artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans, PYLARIFY AI, precision oncology, prostate cancer metastases.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer - 3 year(s) ago
PSMA-targeted PET imaging with piflufolastat F 18, (NCCN) Guidelines® for prostate cancer, PYLARIFY® (piflufolastat F 18) injection, PET imaging of PSMA positive lesions in men with prostate cancer.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment - 3 year(s) ago
Lantheus and RefleXion, biology-guided radiotherapy (BgRT) in prostate cancer using the RefleXion X1™ platform, PET tracer, prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™ - 3 year(s) ago
aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation), aPROMISE with PYLARIFY® (piflufolastat F 18), quantitative assessment of PSMA PET/CT images in prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1PYLARIFY® - 3 year(s) ago
Learn about PYLARIFY®.
Source: PYLARIFY HCPCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 5
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 7Lantheus gets FDA nod for Pylarify PET agent for prostate cancer - 3 year(s) ago
Lantheus Medical Imaging has received approval from the U.S. Food and Drug Administration (FDA) for Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen.
Source: AuntMinnie.comCategories: Latest Headlines, RadiologyTweet
#Lantheus announces collaboration with @Novartis to support #ProstateCancer clinical development. #PYLARIFY #Pluvicto. #ReadNow details on UroToday > https://t.co/jfvO9RXbou https://t.co/lEhsGJTq7R